Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone, and GLP‐1 receptor agonists have been developed to treat T2DM (Hunter & Hoelscher, 2012; Kastin & Akerstrom, 2003; Kastin, Akerstrom, & Pan, 2002; McClean, Parthsarathy, Faivre, & Hoelscher, 2011). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.